Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202302_31390
Abstract: OBJECTIVE The triplet regimen based on the programmed cell death 1 (PD1)/ programmed cell death ligand 1 (PDL1) inhibitors combined radiotherapy and antiangiogenic drugs is a novel therapeutic strategy for hepatocellular carcinoma. We conducted a… read more here.
Keywords: hepatocellular carcinoma; inhibitors combined; pdl1 inhibitors; combined radiotherapy ... See more keywords